BioCentury | Jan 17, 2011
Company News

Centegen, sanofi-aventis deal

...veterinary applications. Centegen will receive license fees and is eligible for milestones and tiered royalties. Centegen...
...of the CEN-102 vaccine, which is in preclinical testing. Further financial terms were not disclosed. Centegen Inc....
Items per page:
1 - 1 of 1
BioCentury | Jan 17, 2011
Company News

Centegen, sanofi-aventis deal

...veterinary applications. Centegen will receive license fees and is eligible for milestones and tiered royalties. Centegen...
...of the CEN-102 vaccine, which is in preclinical testing. Further financial terms were not disclosed. Centegen Inc....
Items per page:
1 - 1 of 1